AstraZeneca (AZN)
(Delayed Data from NSDQ)
$76.87 USD
-0.27 (-0.35%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $76.87 0.00 (0.00%) 5:54 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$76.87 USD
-0.27 (-0.35%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $76.87 0.00 (0.00%) 5:54 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
Zacks News
AZN Stock Slips as Dato-DXd Cancer Study Misses Survival Goal
by Zacks Equity Research
AZN's Daiichi Sankyo-partnered datopotamab deruxtecan fails to show overall survival benefits in a breast cancer study. Stock falls.
CHMP Endorses AstraZeneca's Fasenra in Rare Autoimmune Disease
by Zacks Equity Research
If approved, AZN's Fasenra will be the second biologic approved in the European Union to treat eosinophilic granulomatosis with polyangiitis.
EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer
by Zacks Equity Research
If approved, this will be the first regulatory approval for ABBV's Elahere in the European Union.
Astrazeneca (AZN) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
The latest trading day saw Astrazeneca (AZN) settling at $78.38, representing a -0.66% change from its previous close.
Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs
by Kinjel Shah
FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.
J&J's Rybrevant Receives FDA Nod for Expanded Use in NSCLC
by Zacks Equity Research
With this approval, JNJ's Rybrevant is now approved for a total of four indications in the United States.
Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?
by Kinjel Shah
SNY's reasonable valuation, rising estimates, improving top line and positive pipeline progress are good enough reasons to stay invested in the stock.
Wall Street Bulls Look Optimistic About Astrazeneca (AZN): Should You Buy?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Astrazeneca (AZN) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise
by Zacks Equity Research
MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC.
AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease
by Zacks Equity Research
The FDA okays AstraZeneca's Fasenra for treating adults with eosinophilic granulomatosis with polyangiitis. This is the second approved indication for the drug.
Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering
by Zacks Equity Research
IONS' shares fell after announcing the pricing of its secondary issue of shares, which were at a 12% discount to the previous closing price.
Relay Stock Soars on Upbeat Data From Breast Cancer Study
by Zacks Equity Research
RLAY stock soars on positive interim efficacy data from the early-stage study of its doublet therapy, RLY-2608 in combination with Faslodex, for treating MBC.
GSK's Respiratory Drug Nucala Meets Goal in COPD Study
by Zacks Equity Research
GSK announces positive data from a phase III study of Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD).
Merck Scraps Two Late-Stage Keytruda Studies on Disappointing Data
by Zacks Equity Research
MRK made this decision after an independent committee pointed out that Keytruda did not show improvement in certain types of lung and skin cancers.
QIAGEN and AstraZeneca Expand Pact to Develop CDx in Chronic Diseases
by Zacks Equity Research
QGEN's expanded collaboration with AstraZeneca to focus on developing companion diagnostics beyond oncology.
Why Is Merck (MRK) Up 3.8% Since Last Earnings Report?
by Zacks Equity Research
Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights Visa, AstraZeneca, Disney, FitLife Brands and Utah Medical
by Zacks Equity Research
Visa, AstraZeneca, Disney, FitLife Brands and Utah Medical are included in this Analyst Blog.
Top Analyst Reports for Linde, AstraZeneca & Walt Disney
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AstraZeneca PLC (AZN) and The Walt Disney Company (DIS), as well as two micro-cap stocks FitLife Brands, Inc. (FTLF) and Utah Medical Products, Inc. (UTMD).
J&J's Rybrevant Receives EU Approval for Expanded Use in NSCLC
by Zacks Equity Research
The European Commission approves JNJ's Rybrevant in combination with chemotherapy for treating EGFR-mutated NSCLC following failure of prior therapy.
Roche Obtains Approval For its Rare Blood Disorder Drug in the EU
by Zacks Equity Research
RHHBY gets approval for PiaSky for treating patients suffering from paroxysmal nocturnal hemoglobinuria in the EU.
Insmed Stock Surges 168% in the Past Six Months: Here's Why
by Zacks Equity Research
Shares of INSM soar after it reports positive data from two clinical studies that highlight its encouraging progress with its lung disorder drugs.
AstraZeneca (AZN) Denies Rumors About UK Facility Relocation
by Zacks Equity Research
Per third-party reports, AstraZeneca (AZN) has refuted rumors about considering a change in the relocation of a vaccine manufacturing plant from the U.K. to the United States.
Bristol Myers' (BMY) HCC Combo Drug Accepted for FDA Review
by Zacks Equity Research
Bristol Myers' (BMY) application seeking approval for the Opdivo/Yervoy combo to treat unresectable hepatocellular carcinoma gets accepted for FDA review.
J&J (JNJ) Gets FDA Nod for Chemotherapy-Free Lung Cancer Therapy
by Zacks Equity Research
The approval is based on late-stage study data wherein treatment with J&J's (JNJ) Rybrevant plus Lazcluze cut the risk of disease progression or death by 30% in certain NSCLC patients.
How Should You Play AstraZeneca (AZN) After Q2 Beat, View Raise?
by Kinjel Shah
AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge, with several candidates having blockbuster potential.